Compare ESP & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESP | SERA |
|---|---|---|
| Founded | 1928 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Precision Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.8M | 130.5M |
| IPO Year | N/A | 2021 |
| Metric | ESP | SERA |
|---|---|---|
| Price | $47.13 | $2.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.0K | ★ 62.9K |
| Earning Date | 02-11-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.12% | N/A |
| EPS Growth | ★ 28.72 | N/A |
| EPS | ★ 3.16 | N/A |
| Revenue | ★ $42,600,530.00 | $95,000.00 |
| Revenue This Year | $9.16 | $25.84 |
| Revenue Next Year | $5.68 | $347.37 |
| P/E Ratio | $14.91 | ★ N/A |
| Revenue Growth | ★ 4.90 | 1.06 |
| 52 Week Low | $24.85 | $1.37 |
| 52 Week High | $55.00 | $8.73 |
| Indicator | ESP | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 68.61 | 38.04 |
| Support Level | $46.27 | $2.80 |
| Resistance Level | $47.77 | $3.67 |
| Average True Range (ATR) | 1.37 | 0.26 |
| MACD | 0.22 | -0.08 |
| Stochastic Oscillator | 88.83 | 14.13 |
Espey Manufacturing & Electronics Corp designs, develops, tests, and manufactures specialized military and rugged industrial power supplies and transformers for use in harsh or severe environment applications. Its products and solutions include power converters, power conditioning, high-voltage radar, contract manufacturing, custom engineering, and others. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.